JPMA to Focus on New Developments Including GCP Reform in FY2017: Drug Evaluation Committee

The Japan Pharmaceutical Manufacturers Association’s (JPMA) Drug Evaluation Committee will focus on responding to new developments such as GCP reform, the conditional early approval system, and the clinical research act in FY2017. The members of the committee explained on April...read more